Pfizer Sues Apotex in US Over Generic Version of Lyrica
July 11, 2011
Pfizer Inc., the world’s largest drugmaker, accused Apotex Inc. in a lawsuit of infringing two U.S. patents for the nerve-pain drug Lyrica, reports Bloomberg. Apotex, based in Toronto, plans to market a generic version of Lyrica before the newest patent expires in 2018, Pfizer said in a complaint filed July 8 in federal court in Wilmington, Del. Pfizer claimed it “will be substantially and irreparably harmed” by the alleged infringement. Lyrica generated more than $800 million in sales in the first quarter for New York-based Pfizer, which is selling units and trimming jobs in preparation for pending loss of patent protection for its best-selling drug Lipitor, used to control cholesterol.